ProQR Therapeutics N.V. Company Profile (NASDAQ:PRQR)

About ProQR Therapeutics N.V. (NASDAQ:PRQR)

ProQR Therapeutics N.V. logoProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PRQR
  • CUSIP: N/A
  • Web: www.proqr.com
Capitalization:
  • Market Cap: $149.45 million
  • Outstanding Shares: 24,105,000
Average Prices:
  • 50 Day Moving Avg: $5.12
  • 200 Day Moving Avg: $5.00
  • 52 Week Range: $3.65 - $8.70
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.65
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.21 million
  • Price / Sales: 123.51
  • Book Value: $1.83 per share
  • Price / Book: 3.39
Profitability:
  • EBIDTA: ($46,910,000.00)
  • Return on Equity: -82.16%
  • Return on Assets: -66.16%
Debt:
  • Debt-to-Equity Ratio: 0.17%
  • Current Ratio: 8.22%
  • Quick Ratio: 8.22%
Misc:
  • Average Volume: 33,672 shs.
  • Beta: 0.84
  • Short Ratio: 5.21
 

Frequently Asked Questions for ProQR Therapeutics N.V. (NASDAQ:PRQR)

What is ProQR Therapeutics N.V.'s stock symbol?

ProQR Therapeutics N.V. trades on the NASDAQ under the ticker symbol "PRQR."

How were ProQR Therapeutics N.V.'s earnings last quarter?

ProQR Therapeutics N.V. (NASDAQ:PRQR) issued its quarterly earnings data on Wednesday, May, 17th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. View ProQR Therapeutics N.V.'s Earnings History.

When will ProQR Therapeutics N.V. make its next earnings announcement?

ProQR Therapeutics N.V. is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for ProQR Therapeutics N.V..

Where is ProQR Therapeutics N.V.'s stock going? Where will ProQR Therapeutics N.V.'s stock price be in 2017?

4 brokerages have issued twelve-month target prices for ProQR Therapeutics N.V.'s stock. Their predictions range from $4.50 to $40.00. On average, they expect ProQR Therapeutics N.V.'s stock price to reach $16.38 in the next year. View Analyst Ratings for ProQR Therapeutics N.V..

What are analysts saying about ProQR Therapeutics N.V. stock?

Here are some recent quotes from research analysts about ProQR Therapeutics N.V. stock:

  • 1. According to Zacks Investment Research, "ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. " (9/13/2017)
  • 2. HC Wainwright analysts commented, "Emile Yu – (212-916-3972) / [email protected]/* */ Takeaways From the R&D Day We see multipronged value going forward after last week’s R&D Day. We believe that in the last three years since its IPO, ProQr has executed successfully on a transformation from a one-oligo CF company to an RNA- platform pipeline with multiple orphan/pediatric indications on deck. In doing so, the company has elected to make RNA technology its core competency, and is now doubling down by leveraging this core competency to hit multiple orphan targets. Meanwhile, as we look at the development and clinical plan, we applaud the array of indications that appears designed to minimize risk in formulation and delivery, and shorten development/regulatory time. According to management, the current goal is to have three clinical programs with data by end-2018. In our view, this looks achievable, with Phase 1b CF data on tap for this Sept, the IND for the Phase 1 LCA study now open, and a study in EB planned for 2018. Of note, we highlight that the rising programs in ophtho and derm may allow for a short trial and regulatory timetable, potentially even beating the CF program on a race to commercial value, all else equal." (6/20/2017)

Who are some of ProQR Therapeutics N.V.'s key competitors?

Who are ProQR Therapeutics N.V.'s key executives?

ProQR Therapeutics N.V.'s management team includes the folowing people:

  • Daniel De Boer, Founding Chief Executive Officer
  • Gerard Platenburg, Co-Founder, Chief Innovation Officer
  • Smital Shah, Chief Financial Officer
  • Rene K. Beukema, Chief Corporate Development Officer and General Counsel
  • Noreen Henig, Chief Development Officer

Who owns ProQR Therapeutics N.V. stock?

ProQR Therapeutics N.V.'s stock is owned by many different of institutional and retail investors. Top institutional investors include Jennison Associates LLC (10.36%), Redmile Group LLC (6.69%), INVUS PUBLIC EQUITIES, L.P. (6.00%), Artal Group S.A. (2.10%), Janus Henderson Group PLC (1.63%) and Sphera Funds Management LTD. (1.38%). View Institutional Ownership Trends for ProQR Therapeutics N.V..

Who sold ProQR Therapeutics N.V. stock? Who is selling ProQR Therapeutics N.V. stock?

ProQR Therapeutics N.V.'s stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC. View Insider Buying and Selling for ProQR Therapeutics N.V..

Who bought ProQR Therapeutics N.V. stock? Who is buying ProQR Therapeutics N.V. stock?

ProQR Therapeutics N.V.'s stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Artal Group S.A. and Redmile Group LLC. View Insider Buying and Selling for ProQR Therapeutics N.V..

How do I buy ProQR Therapeutics N.V. stock?

Shares of ProQR Therapeutics N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ProQR Therapeutics N.V.'s stock price today?

One share of ProQR Therapeutics N.V. stock can currently be purchased for approximately $6.20.


MarketBeat Community Rating for ProQR Therapeutics N.V. (NASDAQ PRQR)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  154
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ProQR Therapeutics N.V. (NASDAQ:PRQR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $16.38 (164.11% upside)

Analysts' Ratings History for ProQR Therapeutics N.V. (NASDAQ:PRQR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Chardan CapitalReiterated RatingNeutralHighView Rating Details
6/20/2017HC WainwrightReiterated RatingBuy$40.00HighView Rating Details
10/14/2016Leerink SwannReiterated RatingOutperform$14.00N/AView Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageNeutral$7.00N/AView Rating Details
9/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for ProQR Therapeutics N.V. (NASDAQ:PRQR)
Earnings by Quarter for ProQR Therapeutics N.V. (NASDAQ:PRQR)
Earnings History by Quarter for ProQR Therapeutics N.V. (NASDAQ PRQR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.52)N/AView Earnings Details
5/17/20173/31/2017($0.50)($0.48)$0.32 millionViewN/AView Earnings Details
5/18/2016Q1($0.41)($0.50)$0.22 millionViewN/AView Earnings Details
2/17/2016Q4($0.35)($0.29)ViewN/AView Earnings Details
11/23/2015Q3($0.36)($0.29)ViewN/AView Earnings Details
8/19/2015($0.32)($0.41)ViewN/AView Earnings Details
5/21/2015($0.29)$0.01ViewN/AView Earnings Details
2/26/2015($0.27)($0.30)ViewN/AView Earnings Details
11/24/2014($1.00)($0.53)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ProQR Therapeutics N.V. (NASDAQ:PRQR)
2017 EPS Consensus Estimate: ($2.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.49)($0.49)($0.49)
Q2 20171($0.51)($0.51)($0.51)
Q3 20171($0.49)($0.49)($0.49)
Q4 20171($0.51)($0.51)($0.51)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ProQR Therapeutics N.V. (NASDAQ:PRQR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ProQR Therapeutics N.V. (NASDAQ:PRQR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for ProQR Therapeutics N.V. (NASDAQ:PRQR)
Latest Headlines for ProQR Therapeutics N.V. (NASDAQ:PRQR)
Source:
DateHeadline
finance.yahoo.com logoProQR's Genetic Disorder Candidate Gets Orphan Drug Status
finance.yahoo.com - September 22 at 2:09 PM
finance.yahoo.com logoProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
finance.yahoo.com - September 22 at 2:09 PM
feeds.benzinga.com logoProQR to Present at Two Investor Conferences in September
feeds.benzinga.com - September 21 at 7:25 AM
finance.yahoo.com logoHave Investors Already Priced In ProQR Therapeutics NV’s (PRQR) Growth?
finance.yahoo.com - September 20 at 7:58 AM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Given Neutral Rating at Chardan Capital
www.americanbankingnews.com - September 20 at 6:26 AM
feeds.benzinga.com logoProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
feeds.benzinga.com - September 19 at 7:43 AM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - September 17 at 5:14 PM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Raised to Hold at ValuEngine
www.americanbankingnews.com - September 15 at 9:50 PM
finance.yahoo.com logoProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
finance.yahoo.com - September 12 at 8:48 AM
americanbankingnews.com logoZacks Investment Research Lowers ProQR Therapeutics N.V. (PRQR) to Hold
www.americanbankingnews.com - September 12 at 7:02 AM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - September 9 at 9:08 AM
seekingalpha.com logoProQR’s QRX-421 for Usher Syndrome receives ODD from FDA and EMA
seekingalpha.com - September 7 at 7:54 AM
zacks.com logoProQR's QRX-421 Gets Orphan Drug Designation from FDA and EMA
www.zacks.com - September 7 at 7:54 AM
finance.yahoo.com logoProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
finance.yahoo.com - September 6 at 7:23 AM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - September 2 at 5:38 PM
streetinsider.com logoProQR (PRQR) Reports Completion of Dosing Cystic Fibrosis Patients in QR-010 Phase 1b Trial
www.streetinsider.com - August 31 at 8:59 AM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - August 30 at 11:50 PM
finance.yahoo.com logoProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial
finance.yahoo.com - August 30 at 8:10 AM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - August 29 at 8:40 AM
finance.yahoo.com logoProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
finance.yahoo.com - August 29 at 6:55 AM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - August 22 at 11:22 AM
americanbankingnews.com logoBrokers Offer Predictions for ProQR Therapeutics N.V.'s Q3 2017 Earnings (PRQR)
www.americanbankingnews.com - August 18 at 6:26 AM
globenewswire.com logoProQR Announces Results for the Second Quarter of 2017
globenewswire.com - August 17 at 7:04 AM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 15 at 11:56 AM
americanbankingnews.com logoProQR Therapeutics N.V. (NASDAQ:PRQR) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - August 8 at 7:08 AM
americanbankingnews.com logoProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 9:10 AM
finance.yahoo.com logoProQR's Usher Syndrome Candidate Gets Orphan Drug Status
finance.yahoo.com - July 7 at 8:17 AM
nasdaq.com logoProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
www.nasdaq.com - July 5 at 9:44 AM
streetinsider.com logoProQR (PRQR) Investigational Drug QRX-411 for Usher Syndrome Granted Orphan Drug Designation from FDA & EMA
www.streetinsider.com - July 5 at 9:44 AM
finance.yahoo.com logoProQR's Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
finance.yahoo.com - July 5 at 9:44 AM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 26 at 8:54 AM
americanbankingnews.com logoProQR Therapeutics N.V. (PRQR) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - June 20 at 7:58 AM
seekingalpha.com logoProQR presents R&D day highlights progress and introduces Axiomer, a novel proprietary RNA technology
seekingalpha.com - June 16 at 9:04 AM
finance.yahoo.com logoProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology
finance.yahoo.com - June 16 at 9:04 AM
feeds.benzinga.com logoProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference
feeds.benzinga.com - June 13 at 7:23 AM
finance.yahoo.com logoProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
finance.yahoo.com - June 8 at 8:13 PM
finance.yahoo.com logoProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
finance.yahoo.com - May 31 at 1:02 PM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 7:58 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Short Interest Up 2.2% in April
www.americanbankingnews.com - May 22 at 4:14 PM
americanbankingnews.com logoBrokers Issue Forecasts for ProQR Therapeutics NV's Q3 2017 Earnings (PRQR)
www.americanbankingnews.com - May 19 at 7:28 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 18 at 10:44 AM
finance.yahoo.com logoProQR Announces Results for the First Quarter of 2017
finance.yahoo.com - May 17 at 7:15 PM
finance.yahoo.com logoProQR remembers co-founder Henri Termeer after his unexpected passing
finance.yahoo.com - May 15 at 9:48 AM
finance.yahoo.com logoProQR Announces R&D Day in New York on June 15
finance.yahoo.com - May 9 at 11:00 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Earning Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - May 4 at 10:37 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 3 at 10:03 AM
finance.yahoo.com logoProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
finance.yahoo.com - May 1 at 11:11 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Earning Somewhat Critical News Coverage, Study Shows
www.americanbankingnews.com - April 28 at 3:54 PM
finance.yahoo.com logoProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
finance.yahoo.com - April 27 at 10:36 AM
americanbankingnews.com logoProQR Therapeutics NV (PRQR) Receives Media Sentiment Rating of -0.16
www.americanbankingnews.com - April 22 at 7:32 AM

Social

Chart

ProQR Therapeutics N.V. (PRQR) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff